Literature DB >> 2842157

Treatment of vaginal candidiasis with a single oral dose of fluconazole. Multicentre Study Group.

.   

Abstract

A single dose of 150 mg fluconazole was used to treat 180 patients with clinical and mycological evidence of vaginal candidiasis in an open, non-comparative, multicentre trial. The clinical response to treatment was excellent, with 97% of patients cured or markedly improved after 5 to 16 days. At long-term assessment (27 to 62 days), the proportion cured was 88%. Candida was eradicated from the vagina in 93% of patients at short-term assessment and in 73% at long-term assessment. The rate of relapse, reinfection or recolonization at long-term assessment in patients who had responded at short-term assessment was 23%. The incidence of side-effects was low, and consisted mainly of mild gastrointestinal complaints. Abnormal laboratory test results occurred in 15 of 167 evaluable patients, but all were minor and of minimal clinical significance. Oral fluconazole given in a single dose of 150 mg is an effective, safe and well tolerated treatment for vaginal candidiasis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842157     DOI: 10.1007/BF01962338

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic.

Authors:  M P Bisschop; J M Merkus; H Scheygrond; J Van Cutsem; A van de Kuy
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1979-08       Impact factor: 2.435

3.  Hepatic reactions during ketoconazole treatment.

Authors:  P A Janssen; J E Symoens
Journal:  Am J Med       Date:  1983-01-24       Impact factor: 4.965

4.  European Ethical Review Committee: the experience of an international ethics committee reviewing protocols for drug trials.

Authors:  J M Faccini; P N Bennett; J L Reid
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-20

5.  Treatment of vaginal candidosis with oral ketoconazole.

Authors:  H Van der Pas; F Peeters; D Janssens; E Snauwaert; J Van Cutsem
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1983-03       Impact factor: 2.435

6.  Ketoconazole blocks adrenal steroid synthesis.

Authors:  A Pont; P L Williams; D S Loose; D Feldman; R E Reitz; C Bochra; D A Stevens
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Recurrent vaginal candidiasis. Importance of an intestinal reservoir.

Authors:  M R Miles; L Olsen; A Rogers
Journal:  JAMA       Date:  1977-10-24       Impact factor: 56.272

Review 8.  Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use.

Authors:  J H Van Tyle
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

9.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

  9 in total
  5 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

3.  Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy.

Authors:  W Inman; G Pearce; L Wilton
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Efficacy of fluconazole in the treatment of systemic fungal infections.

Authors:  D Milatovic; A Voss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

Review 5.  Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.

Authors:  F N Vincent-Ballereau; O N Patey; C Lafaix
Journal:  Pharm Weekbl Sci       Date:  1991-04-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.